Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP).
An interim analysis of 40 patients completing Part A showed a 75% confirmed responder rate, improving on the prior >50% readout and reinforcing efficacy signals in the neuromuscular disease.
The drug also continued to show a clean safety profile, with no serious infections, no drug-induced lupus cases, and no safety-related discontinuations.
Investors are now looking to Part B data—up to 52 weeks of treatment in responders—expected by end-2026, as the next key validation point for durability and commercial potential.
Read Next
